Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer

Pathobiology

Volumn 79, Issue 4, 2012, Pages 175-194

  Sterlacci, William ^a   Fiegl, Michael ^b   Tzankov, Alexandar ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cell cycle; Deregulation; Non small cell lung cancer

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ALISERTIB; AURORA A KINASE; AURORA B KINASE; AZACITIDINE; BARASERTIB; CISPLATIN; CYCLIN A; CYCLIN B; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; ENTINOSTAT; ETOPOSIDE; FLAVOPIRIDOL; KI 67 ANTIGEN; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NAVELBINE; PF 3814735; POLO LIKE KINASE; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P57; ROSCOVITINE; TOZASERTIB; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CELL CYCLE REGULATION; CELLULAR DISTRIBUTION; CLINICAL FEATURE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; STAINING;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CYCLINS; HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84858736474     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000336462     Document Type: Review

References (228)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Alberg AJ, Samet JM: Epidemiology of lung cancer. Chest 2003; 123: 21S-49S. (Pubitemid 36135701)
3. Thun MJ, Henley SJ, Calle EE: Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene 2002; 21: 7307-7325. (Pubitemid 35314509)
4. Haussmann HJ: Smoking and lung cancer: future research directions. Int J Toxicol 2007; 26: 353-364.
5. Sasco AJ, Secretan MB, Straif K: Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004; 2:S3-S9. (Pubitemid 39488165)
6. Bray FI, Weiderpass E: Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970-2007. Int J Cancer 2010; 126: 1454-1466.
7. Youlden DR, Cramb SM, Baade PD: The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008; 3: 819-831.
8. Spitz M, Wu X, Wilkinson A, Wei Q (eds): Cancer of the Lung. Oxford, Oxford University Press, 2006.
9. Travis W, Brambilla E, Müller-Hermelink H, Harris C (eds): Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press, 2004.
10. Sakurai H, Asamura H, Watanabe S, Suzuki K, Tsuchiya R: Clinicopathologic features of peripheral squamous cell carcinoma of the lung. Ann Thorac Surg 2004; 78: 222-227. (Pubitemid 38833936)
11. Beadsmoore CJ, Screaton NJ: Classification, staging and prognosis of lung cancer. Eur J Radiol 2003; 45: 8-17. (Pubitemid 36024163)
12. Subramanian J, Govindan R: Lung cancer in never smokers: a review. J Clin Oncol 2007; 25: 561-570. (Pubitemid 350002964)
13. Yang P, Cerhan JR, Vierkant RA, Olson JE, Vachon CM, Limburg PJ, Parker AS, Anderson KE, Sellers TA: Adenocarcinoma of the lung is strongly associated with cigarette smoking: further evidence from a prospective study of women. Am J Epidemiol 2002; 156: 1114-1122. (Pubitemid 35453682)
14. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
15. Jackman DM, Johnson BE: Small-cell lung cancer. Lancet 2005; 366: 1385-1396. (Pubitemid 41443406)
16. Birring SS, Peake MD: Symptoms and the early diagnosis of lung cancer. Thorax 2005; 60: 268-269. (Pubitemid 40522358)
17. Sherwood JT, Brock MV: Lung cancer: new surgical approaches. Respirology 2007; 12: 326-332. (Pubitemid 47164785)
18. Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT, American College of Chest Physicians: Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines, ed 2. Chest 2007; 132: 161S-177S. (Pubitemid 47502806)
19. Salomaa ER, Sällinen S, Hiekkanen H, Liippo K: Delays in the diagnosis and treatment of lung cancer. Chest 2005; 128: 2282-2288. (Pubitemid 41507570)
20. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lungcancer. N Engl J Med 2004; 350: 351-360. (Pubitemid 38101630)
21. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727. (Pubitemid 44283661)
22. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F, National Cancer Institute of Canada Clinical Trials Group, National Cancer Institute of the US Intergroup JBR.10 Trial Investigators: Vinorelbine plus Cisplatin versus observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597. (Pubitemid 41007845)
23. Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043-5051.
24. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR: A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005; 92: 1834-1836. (Pubitemid 40826128)
25. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M: Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
26. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
27. Dimou A, Harrington K, Syrigos KN: From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer. Patholog Res Int 2011; 2011: 312-346.
28. Brundage MD, Davies D, Mackillop WJ: Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122: 1037-1057.
29. Endoh H, Tomida S, Yatabe Y, Konishi H, Osada H, Tajima K, Kuwano H, Takahashi T, Mitsudomi T: Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 2004; 22: 811-819. (Pubitemid 41103592)
30. Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, Lu C, Woodgett J, Seiden I, Johnston M, Keshavjee S, Darling G, Winton T, Breitkreutz BJ, Jorgenson P, Tyers M, Shepherd FA, Tsao MS: Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002; 62: 3005-3008. (Pubitemid 34602385)
31. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8: 816-824.
32. Schneider PM, Praeuer HW, Stoeltzing O, Boehm J, Manning J, Metzger R, Fink U, Wegerer S, Hoelscher AH, Roth JA: Multiple molecular marker testing (p53, C-Ki-ras, cerbB- 2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 2000; 83: 473-479. (Pubitemid 30487860)
33. Malumbres M, Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153-166.
34. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227-230. (Pubitemid 27064710)
35. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57: 3381-3385. (Pubitemid 27355479)
36. Sterlacci W, Tzankov A, Veits L, Zelger B, Bihl MP, Foerster A, Augustin F, Fiegl M, Savic S: A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J Thorac Oncol 2011; 6: 1649-1657.
37. Sterlacci W, Fiegl M, Hilbe W, Jamnig H, Oberaigner W, Schmid T, Augustin F, Auberger J, Obermann EC, Tzankov A: Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol 2010; 5: 1325-1336.
38. Giacinti C, Giordano A: RB and cell cycle progression. Oncogene 2006; 25: 5220-5227. (Pubitemid 44299080)
39. van den Heuvel S, Harlow E: Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993; 262: 2050-2054. (Pubitemid 24041887)
40. Eymin B, Gazzeri S: Role of cell cycle regulators in lung carcinogenesis. Cell Adh Migr 2010; 4: 114-123.
41. Malumbres M, Barbacid M: Mammalian cyclin- dependent kinases. Trends Biochem Sci 2005; 30: 630-641.
42. Peters JM: The anaphase promoting complex/ cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 2006; 7: 644-656.
43. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512. (Pubitemid 29297917)
44. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
45. Malumbres M, Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1: 222-231. (Pubitemid 33741897)
46. Massagué J: G1 cell-cycle control and cancer. Nature 2004; 432: 298-306. (Pubitemid 39551657)
47. Singhal S, Amin KM, Kruklitis R, DeLong P, Friscia ME, Litzky LA, Putt ME, Kaiser LR, Albelda SM: Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol Ther 2003; 2: 291-298.
48. Zhu CQ, Shih W, Ling CH, Tsao MS: Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006; 59: 790-800. (Pubitemid 44211740)
49. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF, Sherr CJ: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993; 7: 1559-1571. (Pubitemid 23234349)
50. Imoto M, Doki Y, Jiang W, Han EK, Weinstein IB: Effects of cyclin D1 overexpression on G1 progression-related events. Exp Cell Res 1997; 236: 173-180. (Pubitemid 27452361)
51. Resnitzky D, Gossen M, Bujard H, Reed SI: Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994; 14: 1669-1679.
52. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Gaeta P, La Rocca R, Merlo G, Chella A, Angeletti CA, Dalla Palma P, Bevilacqua G: Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer 1998; 75: 187-192. (Pubitemid 28100057)
53. Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, Cerny T, Thatcher N: Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected nonsmall- cell lung cancer. Br J Cancer 1996; 73: 294-300. (Pubitemid 26047506)
54. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB: Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992; 52: 2980-2983.
55. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812-1817. (Pubitemid 24116192)
56. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J: Cyclin D1 in nonsmall cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007; 55: 1-14. (Pubitemid 46038884)
57. Yoo J, Jung JH, Lee MA, Seo KJ, Shim BY, Kim SH, Cho DG, Ahn MI, Kim CH, Cho KD, Kang SJ, Kim HK: Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci 2007; 22: 318-325.
58. Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennett WP, Jones RT, Borkowski A, Caporaso NA, Fleming M, Trastek V, Pairolero P, Tazelaar H, Midthun D, Jett JR, Liotta LA, Travis WD, Harris CC: Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 2005; 11: 232-241. (Pubitemid 40075800)
59. Myong NH: Cyclin D1 overexpression, p16 loss, and pRb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell lung carcinoma patients. Cancer Res Treat 2008; 40: 45-52.
60. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J: Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995; 11: 1005-1011.
61. Esposito V, Baldi A, De Luca A, Tonini G, Vincenzi B, Santini D, Persichetti P, Mancini A, Citro G, Baldi F, Groeger AM, Caputi M: Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer. J Clin Pathol 2005; 58: 734-739. (Pubitemid 40956829)
62. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES: Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006; 25: 1620-1628.
63. Li R, An SJ, Chen ZH, Zhang GC, Zhu JQ, Nie Q, Xie Z, Guo AL, Mok TS, Wu YL: Expression of cyclin D1 splice variants is differentially associated with outcome in nonsmall cell lung cancer patients. Hum Pathol 2008; 39: 1792-1801.
64. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS: Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 1999; 59: 2470-2476. (Pubitemid 29242299)
65. Cooper WA, Kohonen-Corish MR, Mc- Caughan B, Kennedy C, Sutherland RL, Lee CS: Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology 2009; 55: 28-36.
66. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H: The clinical significance of cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004; 15: 252-256. (Pubitemid 38262624)
67. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L: Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000; 60: 4000-4004. (Pubitemid 30636572)
68. Volm M, Rittgen W, Drings P: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998; 77: 663-669. (Pubitemid 28059477)
69. Müller-Tidow C, Metzger R, Kügler K, Diederichs S, Idos G, Thomas M, Dockhorn- Dworniczak B, Schneider PM, Koeffler HP, Berdel WE, Serve H: Cyclin E is the only cyclin- dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001; 61: 647-653. (Pubitemid 32128628)
70. Volm M, Koomägi R, Mattern J, Stammler G: Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br J Cancer 1997; 75: 1774-1778. (Pubitemid 27230702)
71. Dobashi Y, Jiang SX, Shoji M, Morinaga S, Kameya T: Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas. J Pathol 2003; 199: 208-220. (Pubitemid 36176027)
72. Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B: Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 2006; 66: 11389-11398. (Pubitemid 46009970)
73. Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-1167. (Pubitemid 39100331)
74. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005; 65: 226-235. (Pubitemid 40070814)
75. Turkson J: STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004; 8: 409-422. (Pubitemid 39359648)
76. Stacey DW: Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003; 15: 158-163. (Pubitemid 36332190)
77. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M: Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002; 62: 7001-7003. (Pubitemid 35424093)
78. Shapiro GI: Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004; 10: 4270s-4275s. (Pubitemid 38812461)
79. Grabsch H, Lickvers K, Hansen O, Takeno S, Willers R, Stock W, Gabbert HE, Mueller W: Prognostic value of cyclin B1 protein expression in colorectal cancer. Am J Clin Pathol 2004; 122: 511-516. (Pubitemid 39281246)
80. Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K: Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 2002; 8: 817-822. (Pubitemid 34742113)
81. Toyoshima F, Moriguchi T, Wada A, Fukuda M, Nishida E: Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpoint. EMBO J 1998; 17: 2728-2735. (Pubitemid 28227119)
82. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988; 241: 353-357.
83. Haga Y, Hiroshima K, Iyoda A, Shibuya K, Shimamura F, Iizasa T, Fujisawa T, Ohwada H: Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer. Ann Thorac Surg 2003; 75: 1727-1732. (Pubitemid 36677202)
84. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, Cordon-Cardo C, Slamon DJ: Inactivation of the retinoblastoma susceptibility gene in non-smallcell lung cancer. The Lung Cancer Study Group. Oncogene 1993; 8: 1913-1919. (Pubitemid 23212425)
85. D'Amico TA, Massey M, Herndon JE 2nd, Moore MB, Harpole DH Jr: A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999; 117: 736-743. (Pubitemid 29163078)
86. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005; 11: 3974-3986. (Pubitemid 40791561)
87. Esposito V, Baldi A, Tonini G, Vincenzi B, Santini M, Ambrogi V, Mineo TC, Persichetti P, Liuzzi G, Montesarchio V, Wolner E, Baldi F, Groeger AM: Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol 2004; 57: 58-63. (Pubitemid 38091312)
88. Cheng YL, Lee SC, Harn HJ, Chen CJ, Chang YC, Chen JC, Yu CP: Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer. Eur J Cardiothorac Surg 2003; 23: 221-228.
89. Panani AD, Maliaga K, Babanaraki A, Bellenis I: Numerical abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH in non-small cell lung cancer. Anticancer Res 2009; 29: 4483-4487.
90. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/ CDKN2 in primary human tumours. Nat Genet 1995; 11: 210-212.
91. Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E: Mechanisms of p16INK4A inactivation in non-small-cell lung cancers. Oncogene 1998; 16: 497-504. (Pubitemid 28062077)
92. Taga S, Osaki T, Ohgami A, Imoto H, Yoshimatsu T, Yoshino I, Yano K, Nakanishi R, Ichiyoshi Y, Yasumoto K: Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma. Cancer 1997; 80: 389-395.
93. Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, Kato H: Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in nonsmall cell lung cancer at stages I and II. Lung Cancer 2001; 34: 207-218. (Pubitemid 33010796)
94. Paulsen M, Ferguson-Smith AC: DNA methylation in genomic imprinting, development, and disease. J Pathol 2001; 195: 97-110.
95. Gray SG, Eriksson T, Ekström TJ: Methylation, gene expression and the chromatin connection in cancer (review). Int J Mol Med 1999; 4: 333-350.
96. Hong YS, Roh MS, Kim NY, Lee HJ, Kim HK, Lee KE, Kwak JY, Kim JY: Hypermethylation of p16INK4a in Korean non-small cell lung cancer patients. J Korean Med Sci 2007; 22:S32-S37.
97. Guzman LM, Koriyama C, Akiba S, Eizuru Y, Castillo D, Corvalan A, Aguayo FR: High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile. Biol Res 2007; 40: 365-372. (Pubitemid 351493262)
98. Hilbe W, Dirnhofer S, Greil R, Wöll E: Biomarkers in non-small cell lung cancer prevention. Eur J Cancer Prev 2004; 13: 425-436. (Pubitemid 39336608)
99. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, Franklin WA, Herman JG, Baylin SB, Bunn PA, Byers T: Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006; 66: 3338-3344.
100. Kurkjian C, Kummar S, Murgo AJ: DNA methylation: its role in cancer development and therapy. Curr Probl Cancer 2008; 32: 187-235.
101. Vigil CE, Martin-Santos T, Garcia-Manero G: Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Des Devel Ther 2010; 4: 221-229.
102. Juergens RA, Vendetti F, Coleman B, Sebree RS, Rudeck MA, Belinsky S, Brock M, Herman J, Baylin S, Rudin CM: Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC). J Clin Oncol 2009; 27: 15s (abstract 8055
103. Packenham JP, Taylor JA, White CM, Anna CH, Barrett JC, Devereux TR: Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. Clin Cancer Res 1995; 1: 687-690.
104. Xiao S, Li D, Corson JM, Vijg J, Fletcher JA: Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res 1995; 55: 2968-2971.
105. Hamada K, Kohno T, Kawanishi M, Ohwada S, Yokota J: Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma. Genes Chromosomes Cancer 1998; 22: 232-240. (Pubitemid 28262200)
106. Herman JG, Jen J, Merlo A, Baylin SB: Hypermethylation- associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996; 56: 722-727.
107. Furonaka O, Takeshima Y, Awaya H, Ishida H, Kohno N, Inai K: Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol Int 2004; 54: 549-555. (Pubitemid 39149845)
108. Kawamata N, Miller CW, Koeffler HP: Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/ INK4b and p18/INK4c) in non-small cell lung cancers. Mol Carcinog 1995; 14: 263-268. (Pubitemid 26111253)
109. Ma H, Chen J, Pan S, Dai J, Jin G, Hu Z, Shen H, Shu Y: Potentially functional polymorphisms in cell cycle genes and the survival of non-small cell lung cancer in a Chinese population. Lung Cancer 2011; 73: 32-37.
110. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Katakura H, Wada H: Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002; 20: 3865-3871.
111. Dworakowska D, Jassem E, Jassem J, Boltze C, Wiedorn KH, Dworakowski R, Skokowski J, Jaskiewicz K, Czestochowska E: Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer. Acta Oncol 2005; 44: 75-79. (Pubitemid 40249131)
112. Kwon MS, Lee YI, Lee KY: p21 as a prognostic factor in non-small cell lung carcinomas. Pathol Res Pract 2006; 202: 849-856. (Pubitemid 44743076)
113. Teramen H, Tsukuda K, Tanaka N, Ueno T, Kubo T, Ando M, Soh J, Asano H, Pass HI, Toyooka S, Miyoshi S: Aberrant methylation of p21 gene in lung cancer and malignant pleural mesothelioma. Acta Med Okayama 2011; 65: 179-184.
114. Fang JY, Lu YY: Effects of histone acetylation and DNA methylation on p21(WAF1) regulation. World J Gastroenterol 2002; 8: 400-405.
115. Rosell R, Felip E: Predicting response to paclitaxel/ carboplatin-based therapy in nonsmall cell lung cancer. Semin Oncol 2001; 28: 37-44. (Pubitemid 32953991)
116. Stordal B, Davey M: Understanding cisplatin resistance using cellular models. IUBMB Life 2007; 59: 696-699. (Pubitemid 350035586)
117. Kartalou M, Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 2001; 478: 23-43. (Pubitemid 32530848)
118. Wei J, Zhao J, Long M, Han Y, Wang X, Lin F, Ren J, He T, Zhang H: p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cells. BMC Cancer 2010; 10: 632.
119. Cheung CT, Hasan MK, Widodo N, Kaul SC, Wadhwa R: CARF: an emerging regulator of p53 tumor suppressor and senescence pathway. Mech Ageing Dev 2009; 130: 18-23.
120. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T, Shepherd FA: Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in nonsmall- cell lung cancer. J Clin Oncol 2007; 25: 5240-5247. (Pubitemid 350232256)
121. Hall PA, Lane DP: p53 in tumour pathology: can we trust immunohistochemistry? - Revisited! J Pathol 1994; 172: 1-4.
122. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878. (Pubitemid 24289415)
123. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000; 6: 4055-4063.
124. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S, Lafitte JJ, Sculier JP: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92: 131-139. (Pubitemid 40188446)
125. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001; 18: 705-719. (Pubitemid 33040631)
126. Huncharek M, Muscat J, Geschwind JF: K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 1999; 20: 1507-1510. (Pubitemid 29385437)
127. Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L, Johnson DH: Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 2001; 19: 448-457. (Pubitemid 32112858)
128. Wang YC, Lin RK, Tan YH, Chen JT, Chen CY, Wang YC: Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol 2005; 23: 154-164.
129. Brown JM, Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391-1399. (Pubitemid 29160097)
130. Lowe SW, Sherr CJ: Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003; 13: 77-83. (Pubitemid 36143931)
131. Sengupta S, Harris CC: p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005; 6: 44-55. (Pubitemid 40064898)
132. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and Cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991. (Pubitemid 44343542)
133. Mohamed S, Yasufuku K, Hiroshima K, Nakajima T, Yoshida S, Suzuki M, Sekine Y, Shibuya K, Iizasa T, Farouk A, Fujisawa T: Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer. Cancer 2007; 109: 2506-2514. (Pubitemid 46906470)
134. De Marinis F, Gebbia V, De Petris L: Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer. Ann Oncol 2005; 16:iv116-iv122.
135. Besson A, Hwang HC, Cicero S, Donovan SL, Gurian-West M, Johnson D, Clurman BE, Dyer MA, Roberts JM: Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007; 21: 1731-1746. (Pubitemid 47076473)
136. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM: Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res 1999; 59: 684-688. (Pubitemid 29076068)
137. Takahashi S, Kamata Y, Tamo W, Koyanagi M, Hatanaka R, Yamada Y, Tsushima T, Takaya S, Fukuda I: Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases. Int J Clin Oncol 2002; 7: 349-355. (Pubitemid 36077317)
138. Pignon J-P, Tribodet H, Scagliotti GV, Douillard J-Y, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, Le Chevalier T, Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol 2006; 24: 366s (abstr 7008
139. Filipits M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, Haddad V, André F, Stahel R, Pignon JP, Soria JC, Popper HH, Le Chevalier T, Brambilla E: Cell cycle regulators and outcome of adjuvant cisplatin- based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007; 25: 2735-2740. (Pubitemid 47123181)
140. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS: Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996; 2: 1204-1210. (Pubitemid 26375403)
141. Tannock I: Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 1978; 62: 1117-1133. (Pubitemid 9015322)
142. Eymin B, Haugg M, Droin N, Sordet O, Dimanche- Boitrel MT, Solary E: p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene 1999; 18: 1411-1418. (Pubitemid 29103629)
143. Hashimoto N, Yachida S, Okano K, Wakabayashi H, Imaida K, Kurokohchi K, Masaki T, Kinoshita H, Tominaga M, Ajiki T, Ku Y, Okabayashi T, Hanazaki K, Hiroi M, Izumi S, Mano S, Okada S, Karasawa Y, Maeba T, Suzuki Y: Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas. Ann Surg Oncol 2009; 16: 395-403.
144. Pertia A, Nikoleishvili D, Trsintsadze O, Gogokhia N, Managadze L, Chkhotua A: Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer. Int Urol Nephrol 2007; 39: 381-387. (Pubitemid 47054829)
145. Qi CF, Xiang S, Shin MS, Hao X, Lee CH, Zhou JX, Torrey TA, Hartley JW, Fredrickson TN, Morse HC 3rd: Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. Leuk Res 2006; 30: 153-163. (Pubitemid 41773335)
146. Sánchez-Beato M, Camacho FI, Martínez- Montero JC, Sáez AI, Villuendas R, Sánchez- Verde L, García JF, Piris MA: Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1- cyclin D3 colocalization in tumor cells. Blood 1999; 94: 765-772. (Pubitemid 29323891)
147. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X: High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997; 94: 6380-6385.
148. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, Lee YY, Bartram CR, Koeffler HP: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995; 55: 2266-2269.
149. Blain SW, Massagué J: Breast cancer banishes p27 from nucleus. Nat Med 2002; 8: 1076-1078. (Pubitemid 35175956)
150. Viglietto G, Motti ML, Fusco A: Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle 2002; 1: 394-400.
151. Pagano M, Tam SW, Theodoras AM, Beer- Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitinproteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-685.
152. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE: Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997; 11: 1464-1478.
153. Nguyen H, Gitig DM, Koff A: Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol Cell Biol 1999; 19: 1190-1201. (Pubitemid 29046861)
154. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M: Ubiquitination of p27 is regulated by CDKdependent phosphorylation and trimeric complex formation. Genes Dev 1999; 13: 1181-1189. (Pubitemid 29233148)
155. Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-199. (Pubitemid 129500937)
156. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, Nabel EG: A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J 2002; 21: 3390-3401. (Pubitemid 34760571)
157. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153-1160. (Pubitemid 35175971)
158. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffer PJ: Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 2000; 20: 9138-9148. (Pubitemid 32246103)
159. Medema RH, Kops GJ, Bos JL, Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000; 404: 782-787. (Pubitemid 30212408)
160. Blagosklonny MV: Are p27 and p21 cytoplasmic oncoproteins? Cell Cycle 2002; 1: 391-393.
161. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J, Eilers M: Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 1999; 18: 5321-5333. (Pubitemid 29465582)
162. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H: Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J 1999; 18: 5310-5320. (Pubitemid 29465581)
163. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62: 4132-4141. (Pubitemid 34791085)
164. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE: ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000; 20: 3210-3223. (Pubitemid 30215033)
165. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-CDK activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 1994; 14: 3683-3694. (Pubitemid 24160776)
166. Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K: Procaspase 3/p21 complex formation to resist Fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ 2000; 7: 721-728. (Pubitemid 30599253)
167. Watanabe J, Sato H, Kanai T, Kamata Y, Jobo T, Hata H, Fujisawa T, Ohno E, Kameya T, Kuramoto H: Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - correlation with proliferation and clinicopathological parameters. Br J Cancer 2002; 87: 81-85.
168. Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998; 58: 1730-1735. (Pubitemid 28215101)
169. Hidaka T, Hama S, Shrestha P, Saito T, Kajiwara Y, Yamasaki F, Sugiyama K, Kurisu K: The combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytoma. Anticancer Res 2009; 29: 597-603.
170. Pateras IS, Apostolopoulou K, Koutsami M, Evangelou K, Tsantoulis P, Liloglou T, Nikolaidis G, Sigala F, Kittas C, Field JK, Kotsinas A, Gorgoulis VG: Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer 2006; 119: 2546-2556. (Pubitemid 44691307)
171. Kobatake T, Yano M, Toyooka S, Tsukuda K, Dote H, Kikuchi T, Toyota M, Ouchida M, Aoe M, Date H, Pass HI, Doihara H, Shimizu N: Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep 2004; 12: 1087-1092.
172. Kondo M, Matsuoka S, Uchida K, Osada H, Nagatake M, Takagi K, Harper JW, Takahashi T, Elledge SJ, Takahashi T: Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. Oncogene 1996; 12: 1365-1368.
173. Biaoxue R, Xiguang C, Hua L, Hui M, Shuanying Y, Wei Z, Wenli S, Jie D: Decreased expression of decorin and p57(KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients. Int J Biol Markers 2011; 26: 9-21.
174. Wikman H, Nymark P, Väyrynen A, Jarmalaite S, Kallioniemi A, Salmenkivi K, Vainio-Siukola K, Husgafvel-Pursiainen K, Knuutila S, Wolf M, Anttila S: CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosomes Cancer 2005; 42: 193-199. (Pubitemid 40094104)
175. Pentimalli F, Giordano A: Promises and drawbacks of targeting cell cycle kinases in cancer. Discov Med 2009; 8: 177-180.
176. Shapiro GI: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-1783. (Pubitemid 46628473)
177. Malumbres M, Pevarello P, Barbacid M, Bischoff JR: CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008; 29: 16-21.
178. Kodym E, Kodym R, Reis AE, Habib AA, Story MD, Saha D: The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells. Lung Cancer 2009; 66: 37-47.
179. Keen N, Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004; 4: 927-936. (Pubitemid 39626216)
180. Jackson JR, Patrick DR, Dar MM, Huang PS: Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007; 7: 107-117. (Pubitemid 46160987)
181. Fu J, Bian M, Jiang Q, Zhang C: Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007; 5: 1-10.
182. Tomonaga T, Nomura F: Chromosome instability and kinetochore dysfunction. Histol Histopathol 2007; 22: 191-197. (Pubitemid 46117105)
183. Xu HT, Ma L, Qi FJ, Liu Y, Yu JH, Dai SD, Zhu JJ, Wang EH: Expression of serine threonine kinase 15 is associated with poor differentiation in lung squamous cell carcinoma and adenocarcinoma. Pathol Int 2006; 56: 375-380. (Pubitemid 43886801)
184. Ogawa E, Takenaka K, Katakura H, Adachi M, Otake Y, Toda Y, Kotani H, Manabe T, Wada H, Tanaka F: Perimembrane Aurora- A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC). Ann Surg Oncol 2008; 15: 547-554.
185. Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, Cheng JQ: Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004; 279: 52175-52182. (Pubitemid 39656591)
186. Smith SL, Bowers NL, Betticher DC, Gautschi O, Ratschiller D, Hoban PR, Booton R, Santibánez-Koref MF, Heighway J: Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 2005; 93: 719-729. (Pubitemid 41486464)
187. Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G: Frequent overexpression of aurora B kinase, a novel drug target, in nonsmall cell lung carcinoma patients. Mol Cancer Ther 2006; 5: 2905-2913. (Pubitemid 44849018)
188. Giet R, McLean D, Descamps S, Lee MJ, Raff JW, Prigent C, Glover DM: Drosophila Aurora A kinase is required to localize DTACC to centrosomes and to regulate astral microtubules. J Cell Biol 2002; 156: 437-451. (Pubitemid 34839893)
189. Hannak E, Kirkham M, Hyman AA, Oegema K: Aurora-A kinase is required for centrosome maturation in Caenorhabditis elegans . J Cell Biol 2001; 155: 1109-1116.
190. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI: The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006; 66: 7668-7677. (Pubitemid 44289225)
191. Hoover RR, Harding MW: Synergistic activity of the aurora kinase inhibitor MK- 0457 (VX-680) with idarubicin, Ara-C, and inhibitors of BCR-ABL. ASH Annual Meeting Abstracts 2006; 108: 1384.
192. Yang H, Burke T, Dempsey J, Diaz B, Collins E, Toth J, Beckmann R, Ye X: Mitotic requirement for Aurora A kinase is bypassed in the absence of Aurora B kinase. FEBS Lett 2005; 579: 3385-3391. (Pubitemid 40800286)
193. Lok W, Klein RQ, Saif MW: Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs 2010; 21: 339-350.
194. Lapenna S, Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8: 547-566.
195. Yap TA, Molife LR, Blagden SP, de Bono JS: Targeting cell cycle kinases and kinesins in anticancer drug development. Expert Opin Drug Dis 2007; 2: 539-560. (Pubitemid 47073077)
196. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rübsamen-Waigmann H, Strebhardt K: Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997; 14: 543-549. (Pubitemid 27090956)
197. Holtrich U, Wolf G, Bräuninger A, Karn T, Böhme B, Rübsamen-Waigmann H, Strebhardt K: Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994; 91: 1736-1740. (Pubitemid 24080280)
198. Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, Fritsch H, Gaschler-Markefski B, Hanft G, Munzert G, von Pawel J: The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010; 5: 1060-1067.
199. Sterlacci W, Wolf D, Savic S, Hilbe W, Schmid T, Jamnig H, Fiegl M, Tzankov A: High transforming growth factor- expression represents an important prognostic parameter for surgically resected nonsmall cell lung cancer. Hum Pathol 2012; 43: 339-349.
200. Sherr CJ: Cancer cell cycles. Science 1996; 274: 1672-1677.
201. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massagué J: Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003; 100: 8430-8435. (Pubitemid 36842562)
202. Mishra L, Shetty K, Tang Y, Stuart A, Byers SW: The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005; 24: 5775-5789. (Pubitemid 43086137)
203. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994; 371: 257-261.
204. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995; 92: 5545-5549.
205. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
206. Pietenpol JA, Stein RW, Moran E, Yaciuk P, Schlegel R, Lyons RM, Pittelkow MR, Münger K, Howley PM, Moses HL: TGFbeta 1 inhibition of C-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 1990; 61: 777-785.
207. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massagué J: Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 1990; 62: 175-185.
208. Kim WS, Park C, Jung YS, Kim HS, Han J, Park CH, Kim K, Kim J, Shim YM, Park K: Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung. Anticancer Res 1999; 19: 301-306. (Pubitemid 29168253)
209. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358. (Pubitemid 30408720)
210. Elliott RL, Blobe GC: Role of transforming growth factor beta in human cancer. J Clin Oncol 2005; 23: 2078-2093. (Pubitemid 46211385)
211. Zhang HT, Chen XF, Wang MH, Wang JC, Qi QY, Zhang RM, Xu WQ, Fei QY, Wang F, Cheng QQ, Chen F, Zhu CS, Tao SH, Luo Z: Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer. Clin Cancer Res 2004; 10: 2359-2367. (Pubitemid 38445694)
212. Anumanthan G, Halder SK, Osada H, Takahashi T, Massion PP, Carbone DP, Datta PK: Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells. Br J Cancer 2005; 93: 1157-1167. (Pubitemid 41670701)
213. Jeon HS, Dracheva T, Yang SH, Meerzaman D, Fukuoka J, Shakoori A, Shilo K, Travis WD, Jen J: SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells. Cancer Res 2008; 68: 9686-9692.
214. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, Lafitte JJ, Sculier JP: Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004; 91: 2018-2025. (Pubitemid 40128768)
215. Sterlacci W, Tzankov A, Veits L, Oberaigner W, Schmid T, Hilbe W, Fiegl M: The prognostic impact of sex on surgically resected non-small cell lung cancer depends on clinicopathologic characteristics. Am J Clin Pathol 2011; 135: 611-618.
216. Visbal AL, Williams BA, Nichols FC 3rd, Marks RS, Jett JR, Aubry MC, Edell ES, Wampfler JA, Molina JR, Yang P: Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004; 78: 209-215. (Pubitemid 38842439)
217. Sterlacci W, Savic S, Schmid T, Oberaigner W, Auberger J, Fiegl M, Tzankov A: Tissue sparing application of the newly proposed IASLC/ATS/ERS classification of nonsmall cell lung cancer shows practical diagnostic and prognostic impact. Am J Clin Pathol 2012, in press.
218. George S, Kasimis BS, Cogswell J, Schwarzenberger P, Shapiro GI, Fidias P, Bukowski RM: Phase I study of flavopiridol in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer. Clin Lung Cancer 2008; 9: 160-165. (Pubitemid 351880855)
219. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C: A phase I trial of the selective oral cyclindependent kinase inhibitor seliciclib (CYC202; R-roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007; 96: 29-37. (Pubitemid 46094635)
220. Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, Chiao J, Armour S, Frame S, Green SR, Gianella-Borradori A, Diéras V, Raymond E: Phase I evaluation of Seliciclib (R-roscovitine), a novel oral cyclin- dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 2010; 46: 3243-3250.
221. Cai D, Byth KF, Shapiro GI: AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclindependent kinases 1 and 2, induces E2F-1- dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res 2006; 66: 435-444. (Pubitemid 43166052)
222. Hoang TM, Favier B, Valette A, Barette C, Nguyen CH, Lafanechere L, Grierson DS, Dimitrov S, Molla A: Benzo[e]pyridoindoles, novel inhibitors of the Aurora kinases. Cell Cycle 2009; 8: 765-772.
223. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM: VX-680, a potent and selective smallmolecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262-267. (Pubitemid 38667616)
224. Plummer E, Calvert H, Arkenau H, Lock V, Squires M, Smith DM, Lewis S, Judson I: A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours. J Clin Oncol 2008; 26: 116s (abstract 2519
225. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H: Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 67: 945-954.
226. Schöffski P, Jones SF, Dumez H, Infante JR, Van Mieghem E, Fowst C, Gerletti P, Xu H, Jakubczak JL, English PA, Pierce KJ, Burris HA: Phase I, open-label, multicentre, doseescalation, pharmacokinetic and pharmacodynamic trial of the oral Aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer 2011; 47: 2256-2264.
227. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S: AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007; 13: 3682-3688. (Pubitemid 46955132)
228. Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, Newlander K, Adams JL, Dhanak D, Yang J, Lai Z, Sutton D, Patrick D: GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 2009; 8: 1808-1817.